Literature DB >> 22809281

A variable degree of autoimmunity in the pedigree of a patient with type 1 diabetes homozygous for the PTPN22 1858T variant.

Francesca Capasso1, Novella Rapini, Gigliola Di Matteo, Manuela Testi, Susanna Arcano, Roberta Lidano, Arianna Petrelli, Paolo Rossi, Simona Piccinini, Maria Luisa Manca Bitti, Federica Angelini.   

Abstract

We investigated whether the PTPN22 C1858T polymorphism is associated with the autoimmune conditions present in the family of a child affected by type 1 diabetes (T1D) carrying the TT genotype (index patient) and the potential immunological effect of the variant. We found that nine family members carried the CT genotype and five suffered from autoimmunity. Interestingly, anti-ZnT8 antibodies were detected in T1D patients and in three healthy relatives. In the TT patient, we showed diminished T-cell proliferation and reduced interleukin-2 (IL-2) and interferon-gamma (IFN-γ) production. A marked reduction of IL-2 was also observed for all CT relatives with autoimmunity and a lack of IFN-γ production was observed for the younger brother of the index patient, heterozygous for the polymorphism. In this family, the C1858T variant might confer a high risk of autoimmunity. Moreover, our data confirm that impaired IL-2 production upon T-cell receptor stimulation is associated with autoimmunity in the carriers of the polymorphism. This study might prompt to extend the panel of risk markers in relatives of subjects affected by T1D.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22809281     DOI: 10.1111/j.1399-5448.2012.00891.x

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  1 in total

1.  PTPN22 1858C>T polymorphism is associated with increased CD154 expression and higher CD4+ T cells percentage in rheumatoid arthritis patients.

Authors:  Yeniley Ruiz-Noa; Jorge Hernández-Bello; Mara A Llamas-Covarrubias; Claudia A Palafox-Sánchez; Edith Oregon-Romero; Pedro Ernesto Sánchez-Hernández; Maria Guadalupe Ramírez-Dueñas; Isela Parra-Rojas; Jose Francisco Muñoz-Valle
Journal:  J Clin Lab Anal       Date:  2018-11-06       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.